Topics:
Atrial Fibrillation
Summary
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 1–2% of the general population.
01/12/2010 00:00:00
Current versions available to download
Current translated versions available to download:
Authors
A. John Camm FESC (Chairperson), Paulus Kirchhof FESC, Gregory Y. H. Lip FESC, Ulrich Schotten, Irene Savelieva, Sabine Ernst FESC, Isabelle C. Van Gelder FESC, Nawwar Al-Attar, Gerhard Hindricks FESC, Bernard Prendergast FESC, Hein Heidbuchel FESC, Ottavio Alfieri FESC, Annalisa Angelini FESC, Dan Atar FESC, Paolo Colonna FESC, Raffaele De Caterina FESC, Johan De Sutter FESC, Andreas Goette, Bulent Gorenek FESC, Magnus Heldal FESC, Stefan Hohnloser FESC, Philippe Kolh FESC, Jean-Yves Le Heuzey FESC, Piotr Ponikowski FESC, Frans H. Rutten
Declarations of Interest of the experts involved in the elaboration of the document.
Possible risks of liver injury with dronedarone
Dronedarone: Pallas Trial Results - August 2011
ESC comments EMA statement on Dronedarone
Endorsed by:
Table of contents: Full Text (ESC Clinical Practice Guidelines)
Abbreviations and acronyms
Preamble
Introduction
- Epidemiology
- Mechanisms of atrial fibrillation
Detection, 'natural' history and acute management
- Definition
- Detection
- "Natural" time course
- Electrocardiogram techniques to diagnose and monitor atrial fibrillation
- Types of atrial fibrillation
- Initial management
- Clinical follow-up
Management
Antithrombotic management
- Risk stratification for stroke and thrombo-embolism
- Antithrombotic therapy
- Anticoagulation therapy with vitamin K antagonist vs control
- Antiplatelet therapy vs control
- Anticoagulation therapy with vitamin k antagonist vs antiplatelet therapy
- Other antithrombotic drug regimens
- Investigational agents
- Current recommendations for antithrombotic therapy
- Risk of bleeding
- Optimal international normalized ratio
- Special situations
- paroxymal atrial fibrilllation
- Perioperative anticoagulation
- Stable vascular disease
- ACS and/ or PCI
- Elective PCI
- Non-St elevation myocardial infraction
- Acute ST segment elevation myocardial infarction with primary percutaneous intervention
- Acute stroke
- Atrial flutter
- Cardioversion
- Tansoesophageal echocardiogram-guided cardioversion
- Non-pharmacological methods to prevent stroke
Rate and rhythm management
- Acute rate and rhythm management
- Acute rate control
- Pharmacological conversion
- "Pill-in-the-pocket" approach
- Direct current cardioversion
Long term management
- Rate and rhythm control
- long term rate control
- Parmacological rate control
- Atrioventricular node abaltation and modification
- Long term rhythm control
- Antiarrhythmic drugs to maintain sinus rhythm
- Left atrial catheter ablation
- Surgical ablation
Upstream therapy
- Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
- Aldosterone antagosnists
- Statins
- Polyunsaturated fatty acids
Specific population
- Heart failure
- Athletes
- Valvular heart disease
- Acute coronoray syndromes
- Diabetes mellitus
- The elderly
- Pregnancy
- Post-operative atrial fibrillation
- Hyperthyroidism
- Wolf-Parkinson-White syndrome
- Hypertrophic cardiomyopathy
- Pulmonary disease
Previous versions
2006: Corrigendum to ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation:
Full Text
Corrigendum
Executive Summary
Corrigendum
2001:Euro Heart Journal 2001; 22, 1852–1923: Atrial Fibrillation (Management of):
Full text | Executive Summary
A complete list of ESC Clinical Practice Guidelines (current and previous versions) endorsed by ESC National Society Members is available here